Standard Chemical & Pharmaceutical Business Summary

Standard Chemical & Pharmaceutical Co. (1720.TW) operates a vertically integrated pharmaceutical business model, generating revenue primarily through the manufacture and global distribution of generic western medicines, active pharmaceutical ingredients (APIs), and dietary supplements. The company’s primary business segments include human prescription drugs—covering circulatory, digestive, respiratory, and metabolic therapeutic areas—as well as animal health products, medical equipment, and a significant retail presence through its YourChance pharmacy chain. Standard leverages its cGMP-compliant and US FDA-inspected facilities to serve domestic hospitals and clinics while aggressively expanding its export footprint in Japan, China, and Southeast Asia. Its primary competitors include YungShin Global Holding, Synmosa Biopharma, and ScinoPharm Taiwan; Standard maintains a leading market position by balancing high-margin specialty generics with a diversified revenue stream from its retail and API divisions. The company was founded in 1967 by Fan Dao-Nan and remains under the strategic guidance of the Fan family. Current leadership is headed by Chairman Chin-Tsai Fan, a graduate of National Taiwan University’s Department of Pharmacy, and President (CEO) Tzu-Ting Fan, who holds a Master’s in Computer Science from the University of California. This executive team is supported by a board that includes notable figures such as Dr. Yuan-Teh Lee, an emeritus professor and former director of National Taiwan University Hospital, and Academician Hwei-Jiung Wang. Significant institutional influence is held by the Fan Dao Nan Foundation, which serves as a key shareholder and ensures long-term stability and alignment with the company’s core mission of healthcare innovation.